News Update

10/recent/ticker-posts

Header Ads Widget

CANCER CLAIM: NCS Demands Probe Into Blessing CEO’s Alleged Fake Cancer, Donation Fraud.

Blessing CEO.

The Nigerian Cancer Society, NCS, has called for a full-scale investigation into alleged false cancer claims and suspected donation misconduct involving social media personality, Blessing Okoro, popularly known as Blessing CEO, amid growing outrage over the credibility of her public fundraising appeal.

In a statement issued by its National Director of Publicity, Bashir Mohammed Ranccas, the Society said the controversy has sparked widespread concern. It highlighted the urgent need for accountability, given the fragile trust surrounding cancer advocacy and support.

The NCS revealed that the influencer reportedly solicited financial assistance from Nigerians, citing a serious health condition, and received substantial donations from sympathetic members of the public.

However, emerging allegations suggesting possible misrepresentation have cast serious doubt over the authenticity of the claims.

Describing the development as disturbing and unethical, the Society warned that any exploitation of cancer narratives for personal gain could severely damage public confidence and jeopardise support for genuine patients battling the disease.

“Cancer is not a tool for manipulation,” the statement stressed, noting that such actions, if proven, could undermine years of advocacy and discourage life-saving generosity from donors.

The NCS further announced plans to involve relevant security agencies to thoroughly investigate the matter and ensure that anyone found culpable faces appropriate sanctions.

It also urged cancer patients and their families to engage only verified platforms when seeking public support, emphasising that the Society maintains structured channels to guide fundraising efforts and patient care.

While calling on donors and partners to exercise caution, the Society reaffirmed that transparency, integrity, and trust remain non-negotiable in the collective fight against cancer.

From Vanguard.

 

Post a Comment

0 Comments